Cidara Therapeutics (CDTX) Common Equity: 2017-2025
Historic Common Equity for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $422.4 million.
- Cidara Therapeutics' Common Equity rose 265.29% to $422.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $422.4 million, marking a year-over-year increase of 265.29%. This contributed to the annual value of $163.3 million for FY2024, which is 2089.14% up from last year.
- As of Q3 2025, Cidara Therapeutics' Common Equity stood at $422.4 million, which was down 15.72% from $501.2 million recorded in Q2 2025.
- Over the past 5 years, Cidara Therapeutics' Common Equity peaked at $501.2 million during Q2 2025, and registered a low of -$18.5 million during Q2 2022.
- Over the past 3 years, Cidara Therapeutics' median Common Equity value was $115.6 million (recorded in 2024), while the average stood at $132.8 million.
- Per our database at Business Quant, Cidara Therapeutics' Common Equity plummeted by 295.82% in 2022 and then surged by 5,317.29% in 2024.
- Quarterly analysis of 5 years shows Cidara Therapeutics' Common Equity stood at $21.6 million in 2021, then plummeted by 166.93% to -$14.4 million in 2022, then spiked by 43.14% to -$8.2 million in 2023, then skyrocketed by 2,089.14% to $163.3 million in 2024, then skyrocketed by 265.29% to $422.4 million in 2025.
- Its Common Equity was $422.4 million in Q3 2025, compared to $501.2 million in Q2 2025 and $141.7 million in Q1 2025.